A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
This is an open-label, two-part, phase 1-2 study designed to determine the safety,
tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered
IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the
WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose
escalation/regimen exploration phase and a phase 2 expansion phase.